Maraviroc matches boosted protease inhibitor treatment over 96 weeks
No evidence of reduced efficacy or increased side-effects when patients switch to generic drugs, comparison study finds
Switch from boosted protease inhibitor to dolutegravir reduces lipids in people with HIV at higher risk of heart disease
Switching from efavirenz to lopinavir/ritonavir has no meaningful impact on neurological function, says UK study
A quarter of people with second-line ART treatment failure in Kenya have exhausted current treatment options
Switching from Atripla to generic-containing regimens can produce large cost savings
Bone density improves in people who switch from tenofovir DF to tenofovir alafenamide
Dolutegravir monotherapy fails to maintain HIV viral suppression, but dolutegravir + lamivudine looks good
Dual antiretroviral regimen maintains durable HIV suppression after switch
